primary%20open-angle%20glaucoma
PRIMARY OPEN-ANGLE GLAUCOMA
Primary open-angle glaucoma (POAG) is a chronic, progressive, usually bilateral disease of the eye with an insidious onset.
It is most often characterized by optic nerve damage, defects in the retinal fiber layer and subsequent visual field loss in the absence of underlying ocular disease or congenital abnormalities.
It is generally asymptomatic until it has caused a significant loss of visual field.
Occasionally, patients with very high intraocular pressure may complain of nonspecific headache, discomfort, intermittent blurring of vision or even halos caused by corneal edema.

Primary%20open-angle%20glaucoma Patient Education

Patient Education

  • Inform and involve patients about the status of their condition, the goals and plans for managing their disease, as well as the risks and benefits involved in such interventions
  • Form a therapeutic alliance with patient and family, and stress that glaucoma is a chronic disease where treatment and follow-up is life-long
  • Educate patients on how to recognize significant changes in their condition so physicians may be alerted
  • Provide emotional support and encouragement to help patients deal with possible issues concerning employment, relationships, diminished functional capacities (eg driving, reading, performance of everyday tasks, sports-related activities)
    • Patients may be referred to support groups or provided counseling
  • Patients should be taught how to perform nasolacrimal occlusion or eyelid closure when applying topical medications to reduce systemic absorption
    • Punctual occlusion and eyelid closure for at least 3 minutes
    • If ≥2 drops are to be instilled, wait at least 5 minutes between drops
Editor's Recommendations
Most Read Articles
Stephen Padilla, Yesterday
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
6 days ago
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
6 days ago
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.